recent share corpor respons includ color
pandem financi impact base busi region trend seen far
revis estim ahead result releas may new number reflect
sizabl revenu hit global declin elect surgeri limit expens
offset updat pt
expect signific neg impact fiscal
report fiscal fourth quarter may period includ extra
month april compar standard calendar first quarter end march
thu incorpor greater neg impact pandem caus
widespread volum declin elect procedur significantli pressur compani
revenu result addit anticip sale suffer fewer larg end-
of-year order sinc custom reduc inventori level preserv cash custom
also postpon purchas capit equip relat fight
compani recent provid updat busi region impact
experienc due review april report
revis number fiscal shown figur page
highlight three thing regard chang first respect sale
bulk order dynam referenc worsen year-over-year revenu declin
model roughli percentag point constant currenc basi account
hit postpon elect procedur estim constant currenc
sale declin second product line experienc greater-than-
usual demand due ventil puls oximetri diabet suppli ecmo
other togeth account compani global
revenu mean approxim sale base experi
degre pressur pandem
third regard expens expect signific de-lever
earn declin substanti revenu compani gener
continu invest employe includ sale forc also
run mani manufactur facil near full capac order provid
inventori support eventu rebound procedur reduc expens
like employe travel benefit cost cut wont recogn
part compani flag anticip neg mix shift
reduc price previous
new price target blend price-to-earnings ev/ebitda multipl respect
adjust fiscal forecast multipl close current mean multipl
compani large-cap peer view appropri compel
develop pipelin numer product driver optimist compani
rebound attract growth rate fiscal pandem subsid
reiter outperform rate stock
pleas see page report import disclosur
outperform rate driven optimist outlook
sustain mid-single-digit top-lin growth trajectori combin mdt/cov
entiti combin cost synergi tax rate improv expect
new meet/exce goal grow adjust ep faster
revenu expect pipelin growth driver like becom focu investor
product contribut meaning first full year commerci
view new continu top-tier top- bottom-lin growth
perform medic devic space
launch surgic robot platform
on-going rollout product
resolut onyx
maintain de market share
us
stabil us spine
strong adopt tavr portfolio
us
return growth spine franchis
out-year top-lin growth acceler
market share loss
continu deterior spine
weak adopt trend new product
diversifi medic technolog servic solut compani presenc
countri combin entiti covidien
merger new oper four segment cardiac vascular group
minim invas therapi group diabet restor therapi group cardiac
vascular group segment manufactur market device-bas medic therapi
cardiac rhythm heart failur crhf coronari structur heart aortic
peripher vascular mitg focus advanc gener surgic technolog
diabet segment manufactur market device-bas medic therapi diabet
restor therapi group segment manufactur market device-bas medic
therapi spine neuromodul surgic technolog
compani report thomson eikon cowen compani
compani report thomson eikon cowen compani
medtron incom statement mm except per share y/i y/i cc good incom non-oper expens tax net dilut share y/i cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
continu util pressur account organ play bigger
role health care deliveri competit dynam global potenti regulatori delay
reject failur devic clinic trial econom sensit price pressur
and/or weaken consum demand develop market econom and/or polit
uncertainti emerg market intellectu properti challeng
continu util pressur competit dynam global potenti
regulatori delay reject failur devic clinic trial econom sensit
price pressur and/or weaken demand develop market econom and/or
polit uncertainti emerg market electrophysiolog clinic commun deem
st jude medic durata lead safe effect yale independ review infus
biolog cite cancer promot effect fluctuat foreign exchang rate
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock corp secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
